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The evaluation of therapies requires the development of patient-reported outcomes
(PROs) that help clinicians to understanding the symptoms, perceptions and feelings of
patients with exacerbations of chronic obstructive pulmonary disease (COPD).
With the aim of obtaining information on the perceptions of patients with COPD, their
exacerbations and expectations of treatment, a random telephone contact survey in six
countries was performed.
From 83,592 households screened, 1100 subjects with symptoms compatible with COPD
were identified. The most frequent symptom was shortness of breath (78%). The most
frequent complaint was that due to their COPD: ‘‘they could not complete the activities
they like to do’’ (54%); 17% (187) of individuals were afraid that their COPD would cripple,
or eventually kill them. Exacerbations generated a mean of 5.1 medical visits/year
(SD ¼ 4.6) with the mean duration of exacerbation symptoms being 10.5 days. Increased
coughing was the exacerbation symptom having the strongest impact on well-being (42%).
Fifty-five percent of patients declared that quicker symptom relief was the most desired
requirement for treatment.
New data are provided on the impact of COPD and its exacerbations on the daily life of
patients. These data will help to develop PROs designed to evaluate the effectiveness of
different therapies for exacerbated COPD.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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M. Miravitlles et al.454Introduction cellular phones, probably those comprising younger peopleChronic obstructive pulmonary disease (COPD) is a common
cause of morbidity and mortality in developed countries.
The age-adjusted mortality rate from COPD doubled from
1970 to 2002 in the United States, whereas rates from stroke
and heart disease decreased by 63% and 52% respectively.1
COPD represents a large economic burden to society. The
mean annual direct medical costs of a patient with COPD in
Spain have been quantified as $18762 and up to $10,812 for
severe patients in the USA.3 In all studies, between 35% and
45% of the costs derived from the attention to exacerba-
tions, particularly the most severe that require hospital
admission.2–5 Patients with COPD, followed in observational
studies in primary care, have about two exacerbations per
year,6 and exacerbations accelerate the rate of decline of
pulmonary function7 and significantly impair the quality of
life of COPD patients, both short-8,9 and long-term.10,11
Because of the lack of validated specific questionnaires to
investigate the impact of exacerbations on well-being,
quantification of the impact of exacerbations on quality of
life has been performed using the same generic and specific
questionnaires used for long-term study of patients in stable
state.12–14 The evaluation of therapies for exacerbations of
COPD requires outcomes focused on the patient. A more
comprehensive knowledge of the symptoms, perceptions
and feelings of patients with exacerbations of COPD is
required to develop patient-reported outcomes (PROs)
taking into account the patient’s perceptions of the positive
and negative aspects of antibiotics and other treatments.15
This survey was designed to obtain information on
patients’ perception of their COPD, their exacerbations
and their expectations about treatment. To date, most
COPD studies are based on interviews with patients
recruited through their treatment centers, which has the
advantage of confirmed COPD status, but the disadvantage
of highly clustered and related cases, as well as a bias risk
towards the more compliant patients under certain influ-
ence of the present therapy. This study targeted a regionally
highly scattered and completely independent sample, facing
the challenge of motivation as well as correct screening. To
collect information from a large sample of individuals in a
reasonable time frame, an international telephone inter-
view was designed.Method
Subject selection
The PERCEIVE study (perception of exacerbations of chronic
obstructive pulmonary disease) is a survey performed by
Psyma International Medical Marketing Research GmbH
(Rueckersdorf/Nuernberg, Germany) using computer-as-
sisted telephone interviewing (CATI) in six countries, using
native speakers in the respective regional main languages:
Germany, France, Italy, Spain, the UK and the USA.
Participation in the survey was voluntary, confidential and
anonymous. In these countries, between 92% and 97% of the
households have telephones. This assumes that approxi-
mately 5% to 7% of households can only be reached by(less relevant to the target group).
The initial sampling technique was a regionally stratified,
fully representative aleatory household contact, based on
existing complete phone data records. To be eligible for the
survey, participants had to be older than 18 years and
to respond affirmatively to several screening questions:
‘‘During the last 12months, which of the following symp-
toms have you suffered from (prompted list of 9
symptoms)?’’ affirming at least one of the following:(a) ‘‘shortness of breath for months to years’’,
(b) ‘‘cough that produces green mucus’’ and
(c) ‘‘frequent respiratory infections that worsen
symptoms’’.
Additionally, respondents only qualified if they
confirmed:(d) ‘‘Have you had 3 months of mucus production during
each of the last two consecutive years?’’ and(e) ‘‘During the last 12 months have you taken medication
for respiratory problems?’’ (excluding asthma) .A pilot phase in Germany and the UK, demonstrated that
the initial frequency of households with a suspected COPD
household member was approximately 4% in Germany and
approximately 3% in the UK. The mentioned screening
process used reduced the household incidence to a figure of
around 1% in both countries. This differs from the COPD
prevalence rate of 4–10% reported in the literature.16,17
This design required n ¼ 1100 interviews across all 6
countries. This allows equal sample precision in the
population estimates with an error of 5% and a power of
80% for a population prevalence of the different respiratory
symptoms of at least 5%, thereby making the global sample
representative of each of the countries.Collection of data
Telephone interviews were carried out by previously trained
interviewers between 09:00 and 22:00 on workdays. The
interview lasted about 15min. The survey questionnaire
(available from the authors on request) was based on 29
‘closed’ questions with additional rating scales. The ques-
tionnaire was developed for this survey and pre-tested. The
impact of COPD on daily life activities was investigated by
reading to the patient a list of 10 activities and asking
whether or not COPD influenced them. Similarly, the impact
of flare-ups on daily life was investigated using a list of 6
activities. Feelings about exacerbations were analyzed by
asking the individuals to score each of 7 sentences on a scale
from 1 to 10, where 1 was equal to ‘‘did not make any
difference to my wellbeing’’ and 10 was equal to ‘‘made life
a great deal more difficult’’. Finally, the importance of each
individual symptom of exacerbation on wellbeing was
investigated again with a score system from 1 to 10, where
1 was equal to ‘‘did not make any difference to my
wellbeing’’ and 10 was equal to ‘‘made life a great more
difficult’’. Results are presented as the percentage of
individuals responding from 8 to 10. Expectations about
treatment of exacerbations were investigated by asking the
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Patient’s perception of exacerbations 455patient to choose from a list of 6 items the most needed in
the treatment of exacerbations.Statistical analysis
A descriptive analysis was made using frequency tables for
the nominal variables and measures of central trends and
dispersion for the continuous variables. The w2 test was used
to analyze the relationship between categorical variables.
The Student’s t-test was used for continuous variables that
were normally distributed and where indicated, non-para-
metric tests were used. All statistical tests were two-sided
and comparisons with a probability of error o5% were
considered significant. Tests were adjusted using the
Bonferroni Correction for multiple comparisons.Results
Characteristics of the population
To reach the required number of interviews, a total of
131,990 telephone contacts were necessary to identify
83,592 eligible individuals. Of these, 3073 (3.6%) provided
incomplete or inconsistent data. Among the rest, 79,419 did
not have chronic respiratory symptoms so were not
included. Ultimately, 1100 (1.37%) questionnaires were
completed (Fig. 1).Figure 1 Disposition of the survey population.The clinical and demographical characteristics of the
individuals surveyed are presented in Table 1. More than half
of the respondents were more than 50 years old; 61% were
female and up to 58% had a significant associated disease.
The most frequently reported symptom was shortness of
breath (78%), followed by cough and production of green
mucus (71%), wheezing was reported by as many as 47% of
participants (Fig. 2).
Impact of COPD on daily life activities
Up to 17% (187) individuals answered that they were afraid
that the disease would cripple them or would eventually kill
them (‘scared patients’), 46% declared that it was a serious
disease that they can control with medication (‘serious
patients’) and only 34% answered that it was mainly a
nuisance but not too serious (‘nuisance patients’). Differ-
ences in characteristics between these three groups are
presented in Table 1.
Patients were asked about 10 different situations or
activities of daily life that potentially could be affected by
COPD. The most frequent answers were that due to COPD:
‘‘they could not complete the activities they like to do’’
(596; 54%) and ‘‘they suffer from sleep disturbances’’ (569;
52%) (Fig. 3).
Frequency and characteristics of exacerbations
A total of 736 (89%) patients declared that they had suffered
at least one episode of ‘flare-up’ of symptoms during the
previous year. Of these, 89% needed to see their doctor due
to these episodes and 21% were admitted to the hospital.
Exacerbations generated a mean of 5.1 visits to the doctor
per patient per year (SD ¼ 4.6). Mean duration of symptoms
of exacerbation was 10.5 days. Frequency and duration of
flare ups increased markedly with age: the duration of flare-
ups among those between 40 and 60 years was 9.8 days
(mean; SD ¼ 10.2 days), it increased dramatically to 14.4 days
(SD ¼ 20.5 days) among those over 60.
Impact of exacerbations of COPD on daily-life
activities
Figure 4 shows the percentage of individuals with the
highest scores,8–10 meaning ‘‘made life a great deal more
difficult’’. Increased coughing was mentioned by 42% of
respondents as having a strong impact on wellbeing,
followed by increasing shortness of breath (37%), fatigue
(37%) and increased production of sputum (35%) (Fig. 4).
During an exacerbation, only 41% declared that they could
continue with their normal life while increasing their usual
medication. Up to 45% had to stay in bed or in couch all day,
and 24% of the whole group or 55% of those who worked had
to stop working due to the exacerbations.
Another set of questions referred to their feelings in
relation to exacerbations. Noteably, for strong impact of
exacerbations on mood, 30% were frightened of the onset of
winter, 27% wanted to be alone or only with few close
friends or family, 22% were very scared of exacerbations and
up to 27% felt very frustrated with themselves.
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Table 1 Characteristics of the population surveyed according to self-reported impact of COPD.
All (n ¼ 1100) ‘Scared patients’
(n ¼ 191)
‘Serious patients’
(n ¼ 502)
‘Nuisance patients’
(n ¼ 377)
Gender, male % 39 40 38 40
Age, yrs (51+) 51% 65% 53%yy 39%,y
Duration of symptoms, yrs (SD) 13.7 (12.3) 16.8 (13.4) 14.6 (13.0) 11.1 (9.8),y
Years since diagnosis (SD) 10.4 (10.4) 12.9 (12.0) 11.0 (11.2) 8.4 (7.7),y
Smoking, %
Yes 36 31 34 42yy
No 35 32 34 37
Ex-smokers 28 37 30 20,
Co-morbidity, %
Sleep disturbances 24 30 25 19y
Cardiac diseases/hypertension 20 32 21 13,
Chronic pain 16 23 18 12y,
Arthritis 16 23 17 12y
Depression/anxiety 13 23 12 8
Diabetes 6 11 6 3y
Other 16 24 16yy 12y
None 42 28 38yy 54,y
Employment, %
Part-time 12 9 16 10
Full-time 31 16 29 41,
Unemployed 10 14 7yy 13yy
Homemaker 10 9 11 10
Retired 33 51 33 22,y
Missing 3 1 3 3
Education, %
University level 21 14 21 27
Preparatory school 24 21 25 24
High school 39 51 39yy 33
Discontinued high school 10 8 9 11
Missing 6 6 7 5
Results are based on two-sided tests. For each significant pair, the key of the category with the smaller column proportion appears
under the category with the larger column proportion.
Tests are adjusted for all pair comparisons within a row of each innermost sub-table using the Bonferroni Correction.
Po0.001 in the comparison with ‘scared patients’.
yPo0.01 in the comparison with ‘scared patients’.
yyPo0.05 in the comparison with ‘serious patients’.
yPo0.001 in the comparison with ‘serious patients’.
Po0.01 in the comparison with ‘serious patients’.
Po0.05 in the comparison with ‘serious patients’.
M. Miravitlles et al.456Expectations about treatment of exacerbations of
COPD
Treatments administered for exacerbations are shown in
Fig. 5. Antibiotics were prescribed to 66% of individuals,
54% received a mucolytic and only 26% received a course of
oral corticosteroids. After presenting a list of 6 items
regarding expectations about treatment, 55% of patients
stated that quicker symptom relief was the most desired
requirement of treatment, followed by longer periods
between flare-ups (40%) and fewer side effects (36%)
(Fig. 6).Discussion
This survey provides new data on the impact of COPD and its
exacerbations on patient’s daily life. Such data are often not
collected in clinical or epidemiological studies despite being
highly relevant to the understanding of how patients feel
about their disease and their expectations with treatment.
In addition, there is a growing interest in patient-centered
care, which requires assessment of patient values, concerns
and preferences. This information is crucial for the devel-
opment of PROs aimed at evaluating the effectiveness of
different therapies for stable and exacerbated COPD.
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Figure 2 Symptoms most frequently reported by survey
respondents.
Figure 3 Proportion of daily life activities affected by COPD
reported by survey respondents.
Figure 4 Percentage of survey respondents reporting symp-
toms with a high impact on wellbeing.
Figure 5 Treatments received for exacerbations of COPD in
the survey respondents.
Figure 6 Ideal characteristics of a COPD therapy as listed by
survey respondents.
Patient’s perception of exacerbations 457The impact of COPD and its exacerbations on the disease
in the daily life of respondents is considerable. Up to 17%
responded that they were afraid that the disease would
cripple them or eventually kill them. These individuals were
older, with a longer duration of the disease, more co-
morbidities and a higher proportion of ex-smokers. The 34%
who responded that the disease was only a nuisance were
significantly younger, with shorter duration of symptoms,
fewer co-morbidities and a higher proportion of active
smokers. This last group probably represented the milder
form of the disease. However, it is important to point out
that some of these patients may have moderate or severe
disease. A similar international telephone survey showed
that patients tend to underestimate their morbidity. There
was a significant disparity between subjects’ perception of
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objective breathlessness scale.18 These results emphasize
the importance of PROs in addition to physiological
measurements to evaluate the results of therapies.
The most important aspect of COPD from the patient’s
perspective is the effect on normal daily life activities. This
negative effect increases during exacerbations, because up
to 45% of individuals had to stay in bed or in couch all day
during the episodes. This is consistent with another study
that showed that symptoms were less important from the
patient’s perspective than the impact of exacerbations on
daily life19 or on health status.11,12,20 Patients with COPD are
markedly inactive in daily life compared with individuals of
the same age group21 and this inactivity is accentuated
significantly during exacerbations.22 Furthermore, patients
with frequent exacerbations are more likely to become
housebound.22 Strategies aimed at increasing physical
activity and preventing exacerbations may improve out-
comes in COPD, since time spent outdoors is significantly
associated with improved health status,22 high levels of
physical activity have a preventive effect on readmissions23
and reducing the frequency of severe exacerbations and
admissions may improve survival.24
The patients interviewed generated a mean of 5 visits to
the doctor for exacerbations in the previous year and 21% of
them were admitted to hospital. A recent survey also
demonstrated a mean self-reported frequency of exacerba-
tions of 4.6 episodes per year.19 Clinical trials consistently
observed a lower frequency of exacerbations, indicating
that patients included in clinical trials may not represent
the whole population of COPD,25 or patients may have
different perceptions than physicians about what constitu-
tes an exacerbation, underlining the importance of PROs. A
further example of the differences between patients’ and
physicians’ perceptions is the duration of exacerbations.
This study showed a mean duration of 10.5 days, extended
to 14.4 days in individuals older than 60 years. Similarly, in
another survey the mean duration was 12.7 days, ranging
from 1 to 119 days.19 However, when data are collected by
the investigators, mean recovery time ranges from 5 to
8 days.26,27 In fact, exacerbations defined by changes in
individual symptoms, as experienced by the patients, are
only weakly related to event-based exacerbations, as
perceived by the physician.28
Exacerbations had a strong influence on mood. A
significant proportion of respondents wanted to be alone
and felt very frustrated with themselves during exacerba-
tions, which ties in with findings that COPD patients
experience significantly more psychological distress, parti-
cularly depression than the general population.29 From our
results it can be hypothesized that frequent exacerbations
might be one of the main causes of this distress.
It is important to note that more than a half of
respondents wished to receive treatments that provide
quicker relief of symptoms of exacerbations and also for
treatments that prolong periods between flare-ups. These
should be the two main goals of treatment, to prevent
exacerbations, but when this is not possible, to treat
quickly. Baseline treatment of COPD aims to reduce the
frequency of exacerbations, but the choice of antibiotic in
infective exacerbations may result in shorter duration of
symptoms26,30 and in prolonged time between episodes.31The knowledge of the expectations of patients tells us what
really matters to them and offers a new perspective in the
design of outcomes for clinical trials.
The survey has been performed using telephone inter-
views. The strengths and weaknesses of this sampling
method have been extensively described elsewhere.18,32 A
possible limitation could be the availability of telephone
lines, but more than 90% of the households in the countries
surveyed have telephones. It is also likely that elderly
subjects residing in chronic care facilities were under-
sampled and finally, this sampling method does not permit
verification of self-reported information. On the other hand,
telephone sampling permits non-clustered sampling of units,
eliminates interviewer control over sample selection and
provides anonymity for the respondent.18
One of the difficulties of telephone sampling is the large
number of calls required to obtain an adequate sample. In
our study, more than 100,000 attempts were required to
obtain 1100 valid interviews, results similar to other
telephone surveys.18 These 1100 interviews represented
1.37% of the screened individuals, percentage that is very
similar to the self-reported prevalence of COPD obtained by
a random postal survey in a population of the same age
group in a recent study in the UK.33 As the diagnosis of COPD
cannot be verified in such a survey, questions on chronic
respiratory symptoms and the use of respiratory medica-
tions, excluding asthma, as surrogate of spirometric
diagnosis of COPD were included. The requirement of a
positive response to all three screening questions could have
provided a more restrictive criterion of COPD; however, to
be included in the survey individuals had to have declared to
suffer from chronic bronchitis and have taken respiratory
medications during the last 12 months in addtion to a
positive response to at least one of the screening questions.
The age was not restricted to those older than 40 or 50, to
permit assessment of GOLD 0 individuals and a recent
international survey showed that up to 11.8% of subjects
aged between 20 and 44 years have GOLD 0 COPD.34 In our
sample, 35% of individuals were non-smokers, which is
consistent with other epidemiological studies of COPD.16,35
Although it is not clear if non-smokers identified in
epidemiological studies or population-based surveys are
really affected by COPD or other chronic respiratory
disease,36–38 no existing consensus exclude non-smokers
from the COPD definition so far39,40 and the inclusion of non-
smokers should not affect the objectives and results of our
study.
In summary, this study provides new data about the
impact of COPD and its exacerbations on daily life of
patients. These new data will help to understand patient’s
perception of their disease and their expectations with
treatment. These data are crucial for the development of
PROs aimed at evaluating the effectiveness of different
therapies for stable and exacerbated COPD.References
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